Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets
Patients aged 18 years or older, male or female.
Willing to participate in the study and having signed a written informed consent form.
Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.
Affiliated with a social security system or benefiting from such a system.
Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.
Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.
History of solid organ transplantation or hematopoietic stem cell transplantation.
Pregnant or breastfeeding women.
Parallel
prospective collection of blood and tumor samples
Procedure/SurgeryThe procedure under study is based on the collection of tissue and blood samples at two time points during the patient's management. The patient will undergo a first sampling at the time of inclusion in the study, followed by a second sampling performed at the time of disease progression. Two types of samples will be collected: blood samples and tumor samples. The protocol-mandated tumor sampling at progression will be performed in the following two situations: 1. If, as part of routine clinical care, a biopsy is planned, an additional tumor sample for the study will be collected. 2. If the patient has consented to undergoing a protocol-specific tumor biopsy at the time of progression
"The primary objective is to assess the association between the immune signature in peripheral blood and the efficacy of immunotherapies in patients with advanced-stage NSCLC
Overall survival of patients with advanced-stage NSCLC treated with immunotherapy according to their immune signature.
Compare immune biomarkers in the blood and in the tumor microenvironment of NSCLC patients
Frequency of Immune Biomarkers in the Blood and Tumor Microenvironment of NSCLC
Compare the expression of immune biomarkers in the tumor microenvironment of localized versus advanced NSCLC
Frequency of Immune Biomarkers in the Tumor Microenvironment of Localized and Advanced NSCLC
Identify new immune biomarkers predictive of immunotherapy efficacy in advanced NSCLC
Frequency of Novel Immune Biomarkers According to Response to Immunotherapies in Advanced NSCLC
Study the HVEM/BTLA axis in localized and advanced NSCLC
Association between HVEM expression and overall survival in localized and advanced NSCLC
Click on the lead sponsor to view all of their trials.
